Milademetan is a small molecule commercialized by Rain Oncology, with a leading Phase II program in Refractory Acute Myeloid Leukemia;Relapsed Acute Myeloid Leukemia. According to Globaldata, it is involved in 14 clinical trials, of which 6 were completed, 2 are ongoing, 1 is planned, and 5 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Milademetan’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Milademetan is expected to reach an annual total of $15 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Milademetan tosylate is under development for the treatment of refractory or relapsed acute myeloid leukemia (AML). The drug candidate is administered orally as a capsule. The drug candidate acts by targeting murine double minute 2 (MDM2) protein.
It was also under development for acute lymphocytic leukemia (ALL), Merkel cell carcinoma, dedifferentiated liposarcoma, multiple myeloma, soft tissue sarcoma, lymphomas, chronic myelogenous leukemia (CML), myelodysplastic syndrome and malignant pleural mesothelioma (MPM), solid tumors including pancreatic cancer, lung cancer, breast cancer, biliary tumor.
Rain Oncology Overview
Rain Oncology, formerly Rain Therapeutics, is a biotechnology company that discovers, develops and translates cancer therapies. It is investigating its lead product candidate milademetan, an oral small molecule, inhibitor of mouse double minute 2 (MDM2) to treat well-differentiated (WD) and dedifferentiated (DD) liposarcoma, merkel cell carcinoma, amplified and advanced solid tumors. The company is also evaluating a RAD52 inhibiting program targeting homologous recombination deficiencies and loss of function of several pathway constituents including BRCA1/2 and PALB2 in breast, prostate, pancreatic, ovarian and other tumors. Rain Oncology is headquartered in Newark, California, the US.
The operating loss of the company was US$77.1 million in FY2022, compared to an operating loss of US$51.5 million in FY2021. The net loss of the company was US$75.7 million in FY2022, compared to a net loss of US$51.4 million in FY2021.
For a complete picture of Milademetan’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.